Novavax

At the Citigroup Biopharma Summit, Novavax announced a strategic shift from a pure COVID vaccine maker to a platform company centered on the adjuvant Matrix‑M. Near‑term drivers are partnerships with Sanofi (up to $200 million in milestones) and Pfizer (a $30 million upfront payment, milestone potential up to $500 million plus royalties). Sanofi has begun shipping NUVAXOVID in the U.S.; Novavax emphasizes gradual market share gains over multiple seasons. At the same time, the company is advancing Matrix‑M research in oncology and a C. difficile candidate, keeping R&D spending lean and viewing the partnerships as the basis for extended financial runway. » Więcej na de.investing.com

Novavax is moving from direct commercialization to a technology-licensing platform and plans to license its saponin-based adjuvant Matrix‑M and nanoparticle protein technology to major pharma partners. The company received $800 million in upfront and milestone payments from Pfizer and Sanofi over the past three years, has identified additional near-term milestones of $200 million, and cut its cost base by 80–90%, extending its financial runway to more than two years. Novavax is targeting non-GAAP profitability in 2028 (requiring revenue > $150 million), sees significant potential for combined COVID‑flu vaccines and expanded oncology applications, and expects multiple upcoming catalysts from partner studies and proof-of-concept data. » Więcej na de.investing.com

Sanofi and Takeda have received approvals in the U.S., the EU and Japan for the Nuvaxovid formulation targeted at the SARS‑CoV‑2 variant XFG for the 2026–2027 vaccination season. The partners will handle distribution in their regions; Novavax will receive license fees and milestone payments tied to approvals without establishing its own sales infrastructure. Nuvaxovid is a protein-based vaccine using recombinant nanoparticle technology, is stored at 2–8 °C, and showed a good tolerability profile in a phase‑4 study. » Więcej na de.investing.com